巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Silk Road Medical

SILK
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Silk Road Medical - 延遲價格・最後更新於 14/01 12:15
最高位
36.670
最低位
34.920
開市價
--
前收市價
37.040
成交量(千)
24.99
成交額(百萬)
7.50
買入
--
賣出
--
每手股數
--
市值(百萬)
1,260.46
市盈率
--
息率
--
差價
--
52週高低
67.490 - 34.810
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Silk Road Medical
證券代碼
SILK.US
所屬板塊
Medical Devices
公司業務
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines the benefits of innovative endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
發行量
34468571
公司總部
1213 Innsbruck Drive
公司網址
https://www.silkroadmed.com
公司電郵
investors@silkroadmed.com
公司電話
+1 408 720-9002
暫無內容

關於

Silk Road Medical(SILK.US)所屬的行業板塊為Medical Devices。
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines the benefits of innovative endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
詳細公司背景可參考: https://www.silkroadmed.com